Comparison of Insulin Glargine Versus NPH Insulin in People with Type 2 Diabetes Mellitus Under Outpatient-Clinic Conditions for 18 Months Using a Basal-Bolus Regimen with a Rapid-Acting Insulin Analogue as Mealtime Insulin

Abstract

Aims: To assess the effects of a structured in-patient diabetes training programme in people with Type 2 diabetes mellitus on a basal-bolus regimen using insulin glargine or NPH insulin and rapid-acting insulin analogues with respect to glycaemic control, weight development and incidence of hypoglycaemia in an outpatient-clinic setting.

Patients and Methods: This was a prospective, non-randomized, single centre, comparative observational study including 119 subjects. Pre-study treatment was a basal-bolus regimen with NPH insulin and a rapid-acting insulin analogue. Subjects either continued with NPH insulin (n=56) or were switched over to insulin glargine (n=63) at the discretion of the investigator (aiming at equal numbers in each group). Patients then attended routine out-patient follow up visits for 18 months.

Results: HbA1c in the insulin glargine group improved statistically significant by -0.49%; [95%CI, -0.26, -0.71; p<0.001; HbA1c at endpoint 6.95±0.71%], whereas in the NPH group the reduction by -0.12% [95%CI, -0.31, 0.06; p=0.189; HbA1c at endpoint 7.22±0.74%] was statistically not significant. After 18 months of treatment the difference between treatment groups was 0.37% (p<0.015). Mean weight gain was significantly higher in the NPH group than in the glargine group (2.1 vs. 0.25 kg; p=0.025). A lower risk of hypoglycaemia in the glargine group (0.50 vs. 0.71 episodes/patient/month) did not reach statistical significance (p=0.081).

Conclusions: Following a structured in-patient diabetes training programme glycaemic control in people with Type 2 diabetes mellitus on a basal-bolus regimen improved significantly only with insulin glargine suggesting that training alone may not be sufficient to further improve metabolic control in relatively well controlled patients on NPH insulin. Therefore, in addition to a structured training programme also the insulin regimen should be optimized, e.g. by introduction of an insulin analogue.

Type 2 diabetes mellitus - basal-bolus regimen - glycaemic control - outpatient treatment - insulin glargine

References

• 1 Cavan D, Cradock S. Structured education programmes and type 2 diabetes.  Diabet Med. 2004;  21 ((Suppl 1)) 10-12
• 2 Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S. et al . Functional and molecular defects of pancreatic islets in human type 2 diabetes.  Diabetes. 2005;  54 727-735
• 3 Garg SK. New insulin analogues.  Diabetes Technol Ther. 2005;  7 813-817
• 4 Hirsch IB. Insulin analogues.  N Engl J Med. 2005;  352 174-183
• 5 Karl DM. The use of bolus insulin and advancing insulin therapy in type 2 diabetes.  Curr Diab Rep. 2004;  4 352-357
• 6 LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities.  Am J Med. 2002;  113 ((Suppl 6A)) 3S-11S
• 7 Lindstrom T, Hedman CA, Arnqvist HJ. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.  Diabetes Care. 2002;  25 1049-1054
• 8 Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities.  Diabetes Metab. 2006;  32 7-13
• 9 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c.  Diabetes Care. 2003;  26 881-885
• 10 Rosenstock J, Daily G, Massi-Benedetti M, Fritsche A, Lin Z, Salzmann A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.  Diabetes Care. 2005;  28 950-955
• 11 Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.  Diabetologia. 2005;  48 1988-1995
• 12 Stumvoll M, Goldstein BJ, Haeften TW van. Type 2 diabetes: principles of pathogenesis and therapy.  Lancet. 2005;  365 1333-1346
• 13 Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.  JAMA. 1999;  281 2005-2012
• 14 Yki-Yarvinnen H. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.  Eur J Clin Invest. 2004;  34 410-416

Correspondence